The nuclear factor-kappa B pathway and response to treatment in breast cancer

被引:30
|
作者
Park, Yeon Hee [1 ,2 ,3 ]
机构
[1] Sungkyunkwan Univ, Sch Med, Div Hematol Oncol, Dept Med, Seoul 06351, South Korea
[2] Sungkyunkwan Univ, Sch Med, Biomed Res Inst, Samsung Med Ctr, Seoul 06351, South Korea
[3] Sungkyunkwan Univ, Sch Med, Samsung Adv Inst Hlth Sci & Technol, Seoul 06351, South Korea
关键词
breast cancer; NF-kappa B; RANKL; EPITHELIAL-MESENCHYMAL TRANSITION; TYROSINE KINASE INHIBITOR; INDUCIBLE CHEMORESISTANCE; CHEMOTHERAPY RESISTANCE; INCREASED APOPTOSIS; THERAPEUTIC TARGET; COLORECTAL-CANCER; XENOGRAFT MODEL; GENE-EXPRESSION; CELLS;
D O I
10.2217/pgs-2017-0044
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The nuclear factor-kappa B (NF-kappa B) pathway is known to contribute to critical signaling in cancer biology, including breast cancer, through promotion of proliferation, angiogenesis, metastasis, tumor progression, inflammation and cell survival. In this review, in vivo and in vitro studies of the NF-kappa B pathway in breast cancer are discussed, focusing on DNA damage and the epithelial-mesenchymal transition associated with breast cancer stem cell properties. The relationships between NF-kappa B signaling and conventional cancer treatments in terms of response to chemo-and radiotherapy will also be discussed. Then contribution and involvement of immune system in the NF-kappa B pathway will be covered. Furthermore, the future perspective of NF-kappa B targeting as an innovative strategy to overcome refractory breast cancer, including recent updates on out-receptor activator of NF-kappa B (RANKing), will be covered.
引用
收藏
页码:1697 / 1709
页数:13
相关论文
共 50 条
  • [31] Coffee inhibits nuclear factor-kappa B in prostate cancer cells and xenografts
    Kolberg, Mark
    Pedersen, Sigrid
    Mitake, Maiko
    Holm, Kristine Lillebo
    Bohn, Siv Kjolsrud
    Blomhoff, Heidi Kiil
    Carlsen, Harald
    Blomhoff, Rune
    Paur, Ingvild
    JOURNAL OF NUTRITIONAL BIOCHEMISTRY, 2016, 27 : 153 - 163
  • [32] A preclinical model for investigation of nuclear factor-kappa B inhibitors in ovarian cancer
    Wilson, Andrew J.
    Lee, Hye-Jeong
    Oshinko, Halina
    Yull, Fiona
    Khabele, Dineo
    CANCER RESEARCH, 2011, 71
  • [33] Nuclear factor-kappa B as potential therapeutic target in human colon cancer
    Plewka, Danuta
    Plewka, Andrzej
    Miskiewicz, Adam
    Morek, Michal
    Bogunia, Edyta
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2018, 14 (03) : 516 - 520
  • [34] Significance of Nuclear Factor-Kappa B (NF-xB) and Survivin in Breast Cancer and Their Association with Radiosensitivity and Prognosis
    Cao, Qian
    Ai, Xiu-Qing
    Mushajiang, Munire
    BREAST CANCER-TARGETS AND THERAPY, 2023, 15 : 175 - 188
  • [35] Nuclear factor-kappa B repression in antiinflammation and immunosuppression by glucocorticoids
    vanderBurg, B
    Liden, J
    Okret, S
    Delaunay, F
    Wissink, S
    vanderSaag, PT
    Gustafsson, JA
    TRENDS IN ENDOCRINOLOGY AND METABOLISM, 1997, 8 (04): : 152 - 157
  • [36] Targeting nuclear factor-kappa B to overcome resistance to chemotherapy
    Godwin, P.
    Baird, A. M.
    Heavey, S.
    Barr, M. P.
    O'Byrne, K. J.
    Gately, K.
    FRONTIERS IN ONCOLOGY, 2013, 3
  • [37] Nuclear factor-kappa B signaling in skeletal muscle atrophy
    Hong Li
    Shweta Malhotra
    Ashok Kumar
    Journal of Molecular Medicine, 2008, 86 : 1113 - 1126
  • [38] Nuclear factor-kappa B signaling in skeletal muscle atrophy
    Li, Hong
    Malhotra, Shweta
    Kumar, Ashok
    JOURNAL OF MOLECULAR MEDICINE-JMM, 2008, 86 (10): : 1113 - 1126
  • [39] Nuclear factor-kappa B is constitutively activated in peritoneal endometriosis
    Gonzalez-Ramos, Reinaldo
    Donnez, Jacques
    Defrere, Sylvie
    Leclercq, Isabelle
    Squifflet, Jean
    Lousse, Jean-Christophe
    Van Langendonckt, Anne
    MOLECULAR HUMAN REPRODUCTION, 2007, 13 (7-8) : 503 - 509
  • [40] Delayed hepatocarcinogenesis through antiangiogenic intervention in the nuclear factor-kappa B activation pathway in rats
    Zhi-Zhen Dong
    Department of Chemotherapy
    Hepatobiliary&PancreaticDiseasesInternational, 2010, 9 (02) : 169 - 174